Shares of Akums Drugs fell over 4% to reach a 52-week low of ₹677.90 following the company’s Q2 FY25 results.
Revenue for the quarter ending September 30, 2024, dipped by 12.5% YoY to ₹1,033.09 crore from ₹1,181.24 crore in Q2 FY24, though it showed a modest 1.4% QoQ increase from ₹1,019.13 crore in Q1 FY25.
On the brighter side, Akums reported significant profit growth. Net profit surged 103.8% YoY to ₹66.65 crore, compared to ₹32.69 crore in the same period last year, and an 8.9% QoQ increase from ₹61.21 crore in the previous quarter. For the first half of FY25, Akums’ revenue slightly declined to ₹2,052.20 crore YoY, but profit rebounded impressively to ₹127.86 crore, marking a sharp recovery from a ₹154.73 crore loss in the first half of FY24.
As of 9:42 am, Akums Drugs shares were trading 4.41% lower at Rs 685.00 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
